OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com
Ultimovacs previously already hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial.
Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial
FDA Approves Opdivo for First-Line Treatment of Urothelial Carcinoma
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
BMS Announces Acceptance of U.S. & EU Regulatory Filings for Neoadjuvant Opdivo
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstrating noninferiority for the co-primary endpoints of Cavgd28 (time-averaged Opdivo serum concentration over 28 days) and Cminss (trough serum concentration at steady state) compared to IV Opdivo. In addition, subcutaneous nivolumab displayed noninferior objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) vs. IV Opdivo. These results will be featured in a late-breaking oral presentation (Abstract #LBA360) at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium from January 25-27, 2024.
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma